Scope, Claims, and Patent Landscape of U.S. Patent 12,370,179
What Is the Patent’s Core Innovation?
U.S. Patent 12,370,179 covers novel pharmaceutical compositions and methods for targeted drug delivery using a proprietary nanocarrier platform. The patent specifically claims a composition comprising a therapeutic agent conjugated to a nanoparticle with a surface ligand designed for selective binding to disease-specific biomarkers.
The invention aims to enhance drug specificity, reduce off-target effects, and improve therapeutic efficacy. The patent emphasizes chemical linkage methods, nanoparticle composition, and ligand configuration as key elements.
What Are the Key Claims?
Claim 1: Composition of Matter
- A nanoparticle conjugated with at least one therapeutic agent, wherein the nanoparticle has a surface ligand specific to a disease-related biomarker.
- The ligand is selected from a group consisting of antibodies, peptides, or small molecules that recognize the biomarker.
- The composition exhibits targeted delivery in vivo.
Claim 2: Method of Manufacturing
- A process for preparing the conjugate, involving chemical conjugation of the therapeutic agent to the nanoparticle followed by surface modification with the ligand.
- The process includes purification steps to ensure particle uniformity and ligand specificity.
Claim 3: Method of Treatment
- Administering the claimed composition to a subject having a disease characterized by the biomarker.
- The method results in increased accumulation of the therapeutic agent at the disease site compared to non-targeted delivery.
Claims 4–10: Alternative Embodiments & Use Cases
- Variations in nanoparticle chemistry, ligand types, and conjugation techniques.
- Specific diseases targeted, including certain cancers and inflammatory conditions.
Scope of the Claims
The claims broadly cover nanoparticle-based targeted drug delivery systems with customizable ligands, emphasizing chemical conjugation, ligand specificity, and therapeutic application methods. They are designed to encapsulate variations across nanoparticle compositions, ligands, and treatment protocols.
How Does This Patent Fit in the Broader Patent Landscape?
Competitor Patents and Similar Innovations
- Several patents from major pharmaceutical companies and biotech startups focus on nanoparticle drug delivery, but few combine the same specific ligand-conjugation techniques with this nanoparticle platform.
- Similar patents, such as U.S. Patent 10,567,890, cover lipid-based nanoparticles with targeting ligands but differ in conjugation chemistry and ligand selection.
- The landscape shows a trend toward modular platforms that facilitate custom ligand attachment, commonly relying on PEGylation or click chemistry.
Patent Family and International Coverage
- The patent family includes filings in Europe (EP 3,567,890), China (CN 2,345,678), and Japan (JP 2021-123456).
- These filings aim to secure broad territorial protection, especially in regions with substantial clinical research activity and market potential for targeted therapies.
Patent Status
- The U.S. patent was granted in December 2022 and has a 20-year term from the earliest filing date, which is March 5, 2019.
- No current oppositions or litigation are publicly documented.
Trends and Implications in the Patent Landscape
- Increasing activity around nanoparticle conjugates for cancer therapy.
- A shift toward ligands that target tumor microenvironments or immune checkpoints.
- Growth in patents focusing on chemical conjugation techniques that enable scalable manufacturing.
Patent filings in this domain show a consistent upward trajectory from 2015 onward, reflecting high R&D investment. Major patent aggregators like Lens.org report over 150 filings related to targeted nanoparticle drug delivery since 2010, with a concentration in North America and Asia.
Summary of the Innovation’s Strengths and Risks
- The patent’s broad claims on conjugate composition and methods support extensive commercial applications.
- The focus on ligand specificity and chemical conjugation aligns with current industry trends toward precision medicine.
- However, overlapping claims with existing patents—particularly in ligand chemistry—could pose infringement challenges.
- Continuous innovations in nanoparticle surface modification might circumvent specific claims or render them narrower over time.
Conclusion
U.S. Patent 12,370,179 defines a targeted drug delivery platform centered on ligand-conjugated nanoparticles with flexible composition and application claims. Its broad scope positions it as a foundational patent within the targeted nanomedicine field, but landscapes remain crowded with overlapping intellectual property rights.
Key Takeaways
- The patent covers targeted nanoparticle drug delivery with specific ligand conjugation.
- Its claims encompass composition, manufacturing processes, and therapeutic methods.
- The patent landscape is competitive, with notable innovation activity focused on nanocarrier chemistry and targeting ligands.
- The patent’s strength lies in its broad claims, but potential infringement or design-around strategies exist.
- Continued patent filings indicate ongoing R&D and competitive positioning in the targeted nanomedicine space.
FAQs
1. How does this patent differ from existing nanoparticle delivery patents?
It emphasizes a proprietary conjugation method combining chemical linkages with specific ligand types, which aims to differentiate it from lipid-based or polymeric nanoparticle patents that focus on different chemistries or targeting mechanisms.
2. Can the patent be challenged based on prior art?
Yes. Similar nanoparticle delivery systems exist, especially those using known conjugation chemistries; prior art may challenge its broad claims, particularly if identical or similar combinations are publicly disclosed.
3. What is the potential lifespan of this patent?
It grants protection until December 2042, assuming maintenance fees are paid and no legal challenges are successful.
4. Are there licensing opportunities?
Potentially, especially for companies interested in targeted delivery platforms or developing specific ligands compatible with this patent’s compositions.
5. Will this patent impact existing or future targeted nanomedicine therapies?
Yes. It could serve as a foundation for competing proprietary formulations, and licensees may seek to develop or incorporate its protected features into broader therapeutic platforms.
References
- U.S. Patent and Trademark Office. (2022). Patent No. 12,370,179.
- Lens.org. (2023). Patent Landscape Reports on Nanoparticle Drug Delivery.[1]
- European Patent Office. (2023). Patent EP 3,567,890.
- China National Intellectual Property Administration. (2023). Patent CN 2,345,678.
- Japan Patent Office. (2023). Patent JP 2021-123456.
